1. Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, October 4, 2018 Subject(s): Androgen Antagonists -- therapeutic useProstatic Neoplasms -- drug therapyAndrogen Antagonists -- adverse effectsCost-Benefit AnalysisDisease ProgressionRandomized Controlled Trials as TopicTreatment OutcomeHumansUnited States
